focus -WSS

focus

author：focus 2025-09-30 00:45:46 - browse：489

Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from Covid-19 vaccines are flowing behind the scenes, going to the contract manufacturers and clinical-trial organizers that turn the shots from lab-bench theory to mass-produced reality.

Both AstraZeneca and Johnson & Johnson publicly committed to not profiting off their products during the pandemic — though AstraZeneca has reserved the right to declare the pandemic over on July 1, even if the World Health Organization has not. Pfizer and Moderna made no such pledge, with Pfizer expected to make $15 billion in vaccine-related revenue this year, while Moderna is forecasting $18.4 billion in vaccine sales.

Contractors hired to test and manufacture these vaccines have enjoyed a share of the profits without the same level of public scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Hospitals are piloting generative AI tools as regulators play catch

Wikipedia

WSS

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Secretariat’s lessons for human medicine

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Hospitals are piloting generative AI tools as regulators play catch

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

explore

focus

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

White House drug czar issues call for 'recovery

New air purifier tech could be key to improving indoor air quality

What health policies could hitch a ride on a spending bill?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA warns medical device makers about rise in fabricated data

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Flagship Pioneering startup Sonata Therapeutics lays off 21

Cancer drug shortages should be causing more outrage

In 'major milestone,' FDA approves first cell therapy for solid tumors

focus

Abridge raises $150m as clinical notes automation market heats up

Abridge raises $150m as clinical notes automation market heats up

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

A new drug could help frostbite victims avoid its ravages

FDA reorg will put new emphasis on investigations, sources say

Today's health inequities arise from racist U.S. history, say experts

hotspot

focus

Wikipedia

Wikipedia